A method was developed to quantitate emamectin benzoate in fish feed at levels between 5 and 15 ppm. The active ingredient is extracted from 20 g medicated feed into aqueous-methanolic solvent by overnight shaking. A solid-phase extraction procedure using a 2 g C 18 cartridge is then used to concentrate the active residue and remove interfering matrix components. The extracted drug and internal standard are eluted from the cartridge, evaporated to dryness, and reconstituted in methanol. A control feed sample and fortified control working standard are simultaneously prepared. Remaining interferences and sample analysis are further separated on a gradient liquid chromatographic system. Recovery of emamectin benzoate from fortified feeds ranged from 97 to 100%, with a coefficient of variation (CV) of 1.2%. Determination of emamectin benzoate in medicated feeds resulted in CVs ranging from 2.3 to 4.2% and recoveries of 88 to 98% of label claim.
A method was developed to quantitate emamectin benzoate in fish feed at levels between 5 and 15 ppm. The active ingredient is extracted from 20 g medicated feed into aqueous-methanolic solvent by overnight shaking. A solid-phase extraction procedure using a 2 g C 18 cartridge is then used to concentrate the active residue and remove interfering matrix components. The extracted drug and internal standard are eluted from the cartridge, evaporated to dryness, and reconstituted in methanol. A control feed sample and fortified control working standard are simultaneously prepared. Remaining interferences and sample analysis are further separated on a gradient liquid chromatographic system. Recovery of emamectin benzoate from fortified feeds ranged from 97 to 100%, with a coefficient of variation (CV) of 1.2%. Determination of emamectin benzoate in medicated feeds resulted in CVs ranging from 2.3 to 4.2% and recoveries of 88 to 98% of label claim. E mamectin benzoate (Merck and Co., Whitehouse Station, NJ) is one of a class of avermectins, or macrocyclic 16-membered lactones (1) (2) (3) . It is prepared as a benzoate salt and consists of 2 homologs, B1a and B1b, which are characteristically present in approximately a 90:10 percent ratio. Avermectins have demonstrated a high potency against a variety of crop pests and human and animal parasites (3) (4) (5) . Specifically, emamectin benzoate targets lepidopteran larvae (6, 7) . A commercial feed additive, Emamectin Benzoate Aquaculture Premix, 0.2% (Schering-Plough Co., Kenilworth, NJ), has been developed for the control of sea lice (Lepeophtheirus sp. and Caligus sp.) in Atlantic salmon and trout. The intended sites of distribution include farm fisheries in the United Kingdom, Canada, Chile, and Norway. The recommended feed concentration is 10 ppm emamectin benzoate when fish are fed at a rate of 0.5% biomass per day. The premix is coated onto the outside surface of pelletized feed in a mixer or blender and then sealed with fish oil to produce a final active concentration between 5 and 15 ppm in medicated feed.
Several methods for the analysis of emamectin benzoate and other avermectins in animal tissues, crops, and feeds have been reported (8) (9) (10) (11) (12) (13) (14) . One method, which describes the determination of ivermectin in medicated feeds, uses sample cleanup by alumina column chromatography followed by both reversed and normal solid-phase extraction (SPE) prior to liquid chromatographic (LC) analysis (15) . The method described below accomplishes sample cleanup by a single-cartridge SPE procedure and subsequent LC chromatographic separation of remaining matrix interferences. Note: Handle emamectin benzoate and des-N-methyl derivative with appropriate eye and respiratory protection. Analysts should wear gloves and a laboratory coat.
METHOD

Apparatus
Sample Pretreatment and Initial Extraction
(a) Sample preparation.-Prior to weighing, thoroughly mix contents of sample containers by inverting several times. Accurately weigh a portion of unground feed equivalent to 0.2 mg emamectin benzoate (i.e., for feed with 10 ppm label claim, weigh 20 g) into a 250 mL centrifuge bottle. Add 6-8 glass beads or marbles. Note: 10 mm glass beads are sufficient for 3.5 mm pelletized feed; commercial glass marbles (ca 15 mm id) are required for larger pellet sizes, such as 10.5 mm. Examine samples after overnight shaking to ensure complete disintegration of feed pellets.
Add 20 mL 0.1% phosphoric acid to the centrifuge bottle, and mix on the Vortex mixer 10 min at high speed. Add 100 mL methanol and 4.0 mL internal standard stock solution, and mix on the Vortex mixer an additional 30 min. Place the centrifuge bottle horizontally on the wrist action shaker overnight (ca 16 h). Remove the centrifuge bottle from the shaker, add 30 mL water, and mix. Let the contents settle (ca 30 min).
(b) Control feed preparation.-Weigh an amount of drug-free feed representative of the batch to be analyzed and equivalent to approximate sample weight in (a) Sample preparation. Proceed as in (a) above, eliminating the addition of internal standard solution.
(c) Fortified control feed (working standard) preparation.
- (1) Single point calibration.-Proceed as in (a) above, except add 4.0 mL emamectin benzoate stock standard solution and 4.0 mL internal standard stock solution to the centrifuge bottle after adding 100 mL methanol. (2) Multilevel calibration.-Into each of 5 centrifuge tubes, weigh an amount of drug-free feed equivalent to the approximate sample weight in (a) Sample preparation. Proceed as in (a) above, with the following changes: After adding 100 mL methanol, pipet 4.0 mL internal standard stock solution into each centrifuge bottle and the volumes of emamectin benzoate stock standard solution indicated in Table 1 .
Solid-Phase Extraction
Assemble the SPE manifold and position test tubes and SPE cartridges. Condition cartridges with ca 5 mL methanol followed by 5 mL water. Do not let cartridges dry. After adding 5 mL methanol-water (70 + 30) to each SPE cartridge, attach an adaptor and filtration column. Add ca 50 mL of each sample, control feed, and working standard preparation to the filtration column/SPE cartridge assemblies.
After sample loading is complete, remove adaptors and filtration columns from the SPE cartridges. Wash each cartridge with two 10 mL portions of methanol-water (70 + 30) followed by two 5 mL portions THF-water (40 + 60). Dry cartridges briefly under vacuum for ca 30 s to remove residual solvent. Elute emamectin benzoate and internal standard from each cartridge with 2 separate 5 mL aliquots of 2% ammonium hydroxide in ethanol. Note: Approximate flow rates for loading and elution steps are 1.5-2.0 mL/min; approximate flow rates for cartridge conditioning and wash steps are 2.0-3.0 mL/min.
Place test tubes containing eluted solvent in the rack of the sample concentrator and evaporate to dryness at 50°C under a 1282 FARER ET AL.: JOURNAL OF AOAC INTERNATIONAL VOL. 82, NO. 6, 1999 stream of nitrogen. Reconstitute active and internal standard by adding 1 mL methanol and mixing on a Vortex mixer for 30 s. The reconstituted solutions of sample, working standard, and control feed are injected onto the chromatographic system.
Liquid Chromatography
(a) Operating conditions.-Column temperature, 50°C; detector wavelength, 244 nm; injection volume, 10 µL; total run time, 40 min; mobile phase A, 0.1% phosphoric acid-acetonitrile (60 + 40); mobile phase B, acetonitrile; mobile phase C, THF; gradient conditions and flow rates are given in Table 2 .
(b) System suitability.-To check system suitability, perform 5 replicate injections of the 10 ppm working standard solution. The coefficient of variation (CV) of the ratios of emamectin benzoate B1a peak areas to internal standard B1a peak areas should be <1.5%. Calculate the resolution between 2 peaks (at least 1.8) and tailing factor of emamectin benzoate B1a peak (not more than 1.8). For multilevel calibration, inject 5, 7.5, 10, 12.5, and 15 ppm working standard solutions. Construct a calibration curve by plotting response of working standard solutions (peak area ratio of emamectin benzoate B1a to internal standard B1a) versus amount (µg) injected. The correlation coefficient for the standard curve should be >0.9950. The y-intercept should correspond to not more than 5% of the response ratio of the 10 ppm working standard solution.
(c) Chromatographic procedure.-Follow injections of working standard solutions with injections of sample and control feed solutions. Perform duplicate injections of samples bracketed by multiple standard injections. Measure the peak areas of emamectin benzoate B1a and internal standard B1a peaks for each chromatogram and calculate peak area ratios as described below. Figure 1 shows representative chromatograms.
Calculation
Determine the concentration of emamectin benzoate in feed samples. where A = peak area ratio of emamectin benzoate B1a to internal standard B1a in the sample; B = peak area ratio of emamectin benzoate B1a to internal standard B1a in the working standard; C = concentration of emamectin benzoate in the stock standard solution (µg/mL); D = sample weight, (g); and 4 = volume of emamectin benzoate stock standard pipetted into working standard. where A = peak area ratio of emamectin benzoate B1a to internal standard B1a in the sample; B = intercept from the calibration curve; C = slope of the calibration curve; and D = sample weight, (g).
Results and Discussion
The objective in developing this procedure was to separate emamectin benzoate from potentially interfering feed matrix components and drug impurities and to accurately and reproducibly quantitate active residues at low levels. Highlights of the development and validation of the method are presented.
Development of Sample Pretreatment and Initial Extraction
The procedure specifies direct extraction of unground medicated feed. The elimination of a grinding step as part of the initial sample pretreatment is justified as follows: First, the manufacturing process involves a "surface coating" technique in which the premix is applied only to the outside surface of the feed pellets in a blender or mixer, and then sealed with a layer of fish oil. This process (in contrast to an alternative procedure in which the drug is added to feed components and subsequently pelletized or extruded) facilitates extraction of the drug into the methanolic solvent. Second, the active residue, which is solubilized in the surface oil layer, could potentially be lost during grinding by adherence to the walls of the mill or mixer. Finally, the pellet disintegration steps of the sample preparation procedure prevent incomplete extraction of residual drug from unground feed. The addition of glass beads or marbles serves to initially break up and then totally disintegrate the pellets during the mixing and shaking steps, thereby extracting emamectin benzoate. During method development, most smaller pelletized feeds (3.5 mm diameter) disintegrated within 6 h of shaking, with recoveries approximating those obtained for samples shaken overnight. However, larger size pellets (10.5 mm diameter) and very hard pellets required overnight shaking for complete disintegration.
Development and Optimization of SPE Procedure
Prior to SPE, the sample solvent strength was adjusted to methanol-water (70 + 30). This weaker solvent concentration maximizes retention on the C 18 sorbent bed while maintaining the solubility of emamectin benzoate and internal standard. The 50 mL loading volume is needed to obtain a sufficient analyte concentration for UV detection (200 µg emamectin benzoate results in a signal of about 120-140 mV). An internal standard method eliminates the tedious quantitative addition of 50 mL sample supernatant in the cartridge loading step, and approximate volumes may be used.
Various SPE cartridge types were examined, including SCX, C 18 , C 8 , and silica. Maximum retention and highest recoveries were obtained with the C 18 sorbent. Bed sizes from 500 mg to 5 g were evaluated; 2 g was the smallest mass sorbent which retained the compounds of interest without solute breakthrough when the 50 mL loading volume was used. It FARER ET AL.: JOURNAL OF AOAC INTERNATIONAL VOL. 82, NO. 6, 1999 1285 should be noted that the feed ingredients in these studies (including oil, about 30%; protein, about 50%; grain products; vitamins; minerals; fiber; and fishmeal) accounted for most of the loading mass. The original method specified only one wash solvent, methanol-water (70 + 30). A second wash step was later included when samples formulated from new feed sources were found to contain additional components which interfered with LC analysis in the area of interest and quantitation of emamectin benzoate. A solvent wash of THF-water (40 + 60) selectively removed closely eluting components while allowing retention of active residue and internal standard on the sorbent bed.
Optimization of Chromatography
Although the SPE procedure removed the bulk of matrix interferences, residual oils and fats contained in reconstituted solutions caused LC "column fouling" and chromatographic distortion after multiple injections. The column wash step of THF-acetonitrile (50 + 50), which followed the LC gradient separation, removed these otherwise retained lipophilic matrix components; a column temperature of 50°C maximized their partitioning into the mobile phase. A C 8 chromatographic column was specified (in contrast to the C 18 column used in the analysis of premix) because of its lower affinity for these lipophilic components.
Validation
(a) Specificity.-The method adequately resolved both emamectin benzoate and internal standard from feed matrix components. As mentioned previously, these components consist of a range of potential interferences which are for the most part removed in the initial SPE cleanup; any residual closely eluting compounds are then subsequently separated during chromatographic analysis (Figure 1 ). The specificity of the chromatographic system was also evaluated with respect to 6 closely related compounds. The chromatographic method resolved emamectin benzoate and internal standard from 4 related compounds and from 2 others which eluted after 25 min (Figure 2) .
Nineteen other fish medications, which are potential interferences, were evaluated for method specificity (Table 3) . Solutions of each compound were prepared at the appropriate feed incorporation rate and injected onto the chromatographic system. In each case, complete resolution from both the SCH 58854 and internal standard peaks was obtained.
(b) Linearity.-Linearity was examined over a range of 50-150% of the nominal 10 ppm sample concentration. Duplicate sets of solutions of emamectin benzoate were prepared at 3 levels, carried through the SPE extraction procedure, and chromatographed. A linear response was obtained, with a correlation coefficient of 0.9996 and an equation for the line of y = 0.0073x + 0.0405.
(c) LC system precision.-During the chromatographic analysis, the LC column was submitted to a range of mobile phase conditions ranging from intermediately polar in the initial gradient program [0.1% phosphoric acid-acetonitrile (60 + 40)] to relatively strong in the final column cleanup step [THF-acetonitrile (50 + 50)]. An important aspect of method validation, then, was evaluation of the reproducibility of mobile phase conditions from injection to injection. For this purpose, system precision experiments were performed by injecting 5 replicate injections of 6 individually prepared working standard solutions on different days using different mobile phases. As shown in Table 4 , peak area CVs for emamectin benzoate and internal standard were <3.0 and 2.7%, respectively, for 6 trials of 5 replicate injections. Peak area ratios (emamectin benzoate/internal standard) were <0.6%, indicating good system precision and chromatographic reproducibility.
(d) Method precision.-Two studies were performed to evaluate method precision. First, one medicated feed batch was sampled from 4 locations of a Hobart blender, and duplicate preparations were assayed from each location. Next, 6 replicate preparations from each of 3 different batches of medicated feed were analyzed. The data are outlined in Tables 5 and 6. The average of duplicate preparations for medicated feed sampled from top, middle, bottom, and sides of the Hobart blender were between 91.5 and 98.5% of label claim, with a batch average of 94.6%. CVs ranged from 0.4 to 6.1%, with a batch average of 4.2%. Averages for 6 replicate preparations from 3 medicated feed batches were 97.5, 88.0, and 93.9% of label claim, with CVs of 3.2, 2.3, and 2.8%, respectively.
The wide range of CVs in the first case for medicated feed sampled from 4 blender locations is most likely due to feed-mixing variance. Results for replicate sample preparations from composite samples (second study) show more acceptable CVs, at or below 3.2%.
(e) Recovery.-Recovery of active residue from the sample matrix was evaluated by fortifying control feed with emamectin benzoate at 3 levels, approximately 5, 10, and 15 ppm. As shown in Table 7 , good recoveries of between 97.0 and 100% were obtained, with an average of 98.8% and a CV of 1.2%.
Conclusion
This method was demonstrated to be suitable for analysis of emamectin benzoate in fish feed at the 10 ppm level. Recoveries of emamectin benzoate from feed in fortified samples averaged 98.8%, with a CV of 1.2%. Recoveries from medicated feeds ranged from 88.0 to 97.5%, with CVs between 2.3 and 4.2% The chromatographic method was linear, precise, and specific with respect to potential interferences such as feed matrix components, other fish medications, and emamectin benzoate-related substances.
